Table 3. Effect of concentration on apparent size of lipid-drug nanoparticlesa.
| Lipid concentration (mM) |
Particle size (nm)b | ||
|---|---|---|---|
|
| |||
| Control | ATV-LNPs | DRV-LNPs | |
| 10 | 36.2 ± 7.4 | 46.3 ± 5.7 | 33.9 ± 3.8 |
| 5 | 36.3 ± 6.7 | 53.6 ± 5.2 | 38.6 ± 5.1 |
| 1 | 34.0 ± 4.5 | 49.6 ± 3.6 | 13.8 ± 2.6 |
| 0.25 | 32.1 ± 4.6 | 43.7 ± 3.2 | 14.3 ± 1.0 |
| 0.05 | 33.1 ± 4.5 | 37.2 ± 2.8 | 10.3 ± 1.3 |
| 0.01 | 32.4 ± 4.5 | 37.8 ± 2.7 | 8.9 ± 1.0 |
a
Lipid-drug nanoparticles containing ATV or DRV with a fixed lipid-to-drug molar ratio (8 : 1) or control (without drug) were prepared as described in Materials and Methods.
b
The apparent size of particles at indicated concentrations and dilution were measured by PCS and the particle diameters were expressed as mean ± SD of 4 replicates.